SAEN
SAEN clinical trials: Genenta Science S.p.A.
Every trial on ClinicalTrials.gov where Genenta Science S.p.A. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 3
- Trials linked
- 3
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
SAEN on the catalyst calendar · SAEN registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| May 27, 2026Actual | NCT03866109A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMTGenenta Science · Glioblastoma Multiforme | SAENLead | Phase 1/Phase 2 | Terminated | Locked | Locked | Locked |
| Jan 23, 2026Actual | NCT06716853A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From...Genenta Science · Clear Cell RCC | SAENLead | Phase 1/Phase 2 | Terminated | Locked | Locked | Locked |
| Apr 2, 2021Actual | NCT03875495A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)Genenta Science · Multiple Myeloma | SAENLead | Phase 1/Phase 2 | Terminated | Locked | Locked | Locked |
- Primary completion May 27, 2026ActualPhase 1/Phase 2NCT03866109A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMTGenenta Science · Glioblastoma MultiformeTerminatedSAENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 23, 2026ActualPhase 1/Phase 2NCT06716853A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From...Genenta Science · Clear Cell RCCTerminatedSAENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2, 2021ActualPhase 1/Phase 2NCT03875495A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)Genenta Science · Multiple MyelomaTerminatedSAENLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 3 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner